What question did this study set out to answer?

June 7, 2026

2878-LB: Trends in Automated Insulin Delivery Initiation among Newly Diagnosed Adults with Type 1 Diabetes: A T1D Exchange Multicenter Study

Key Points

To increase early AID initiation among newly diagnosed adults with type 1 diabetes.
Utilized quality improvement tools such as process maps and Plan-Do-Study-Act cycles.
Conducted a retrospective multicenter descriptive analysis involving 5 adult centers.
Compared trends from 2023 to 2025 in AID initiation among newly diagnosed adults.
Median time to AID initiation decreased from 5-17.5 months in 2023 to 0-7 months in 2025.
New-onset AID users initiating within 6 months increased from 14%-67% to 50%-100% by 2025.
Mean HbA1c decreased across all centers from pre-AID initiation to the end of the calendar year following AID initiation.

Abstract

Introduction and Objective: Automated insulin delivery (AID) systems improve glycemic outcomes for adults with type 1 diabetes (T1D), yet timely initiation following diagnosis remains suboptimal. We aimed to increase early AID initiation among newly diagnosed adults with T1D Methods: Six adult centers from the T1D Exchange Quality Improvement Collaborative utilized quality improvement tools such as process maps, Ishikawa diagrams, effort impact matrices, and Plan-Do-Study-Act cycles to increase AID initiation among newly diagnosed adults with T1D. We describe a retrospective, multicenter descriptive analysis using aggregated data from 5 centers and compared trends from 2023-2025 Results: Across the 5 centers, 158, 106, and 104 adults were newly diagnosed with T1D in 2023, 2024, and 2025, respectively. Median time to AID initiation decreased from a range of 5-17.5 months in 2023 to 0-7 months in 2025. New-onset AID users who initiated AID within 6 months ranged from 14%-67% at baseline and increased to 50%-100% in 2025. Rates increased across all centers from year to year. Mean HbA1c decreased across all centers from pre-AID initiation to the end of calendar year following AID initiation Conclusion: Multi-center QI initiatives are feasible and effective strategies in promoting timely initiation of automated insulin delivery following T1D diagnosis Disclosure O. Odugbesan: None. T.R. Bol: None. N. Rioles: None. M. Basina: None. K. Jones: Consultant; Current; Sanofi. G. O'Malley: Research Support; Ended; Dexcom, Inc. Research Support; Current; Abbott, MannKind Corporation. D. Plante: None. G. Aleppo: Advisory Panel; Current; Medscape, Tandem Diabetes Care, Inc. Consultant; Current; Eli Lilly and Company, Dexcom, Inc., Insulet Corporation. Research Support; Current; AbbVie Inc., Bayer, Fractyl, Insulet Corporation, MannKind Corporation, Tandem Diabetes Care, Inc., Medtronic. N. Mathioudakis: None.

Mark Helpful

Bookmark

Relay